Skip to main content
Erschienen in: Irish Journal of Medical Science (1971 -) 1/2022

16.02.2021 | Original Article

Symptoms to script: delays in tuberculosis treatment in the west of Ireland

verfasst von: Conor Grant, Jack McHugh, Ciara Ryan, Margaret Scarry, Anthony O’Regan, Helen Tuite, Catherine Fleming

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

The first pillar of the End-TB Strategy is “early diagnosis and prompt treatment”. Nevertheless, long delays in starting tuberculosis (TB) treatment are reported. We aimed to describe the demographics and clinical features of TB in the west of Ireland and better understand the delays in treatment.

Methods

We conducted a retrospective chart review of all patients diagnosed with active TB who attended the Galway University Hospital (GUH) TB clinic from 2014 to 2018.

Results

Eighty-five patients were diagnosed with TB and attended our clinic. Ten (12%) patients were receiving immunosuppressive therapy, 8 (9%) had drug resistance, and 41 (48%) had extra-pulmonary disease. Patients with extra-pulmonary disease had a longer length of stay before treatment (11 vs. 4 days; p = 0.006). Patients older than 55 had a longer length of stay before (16 vs. 5 days, p = 0.0001) and during (36 vs. 11 days, p = 0.004) treatment and were readmitted more frequently than younger patients. A total of 36% of patients were born outside Ireland.
Non-Irish patients were younger (mean age 35 vs 48; p = 0.004) and more frequently had drug resistance (19% vs. 4%, p = 0.02). The median time from symptom onset to hospital presentation was 76 days (IQR 35–146 days) and the median time from first hospital presentation to TB treatment was 11 days (IQR 5–51 days).

Conclusion

TB patients experienced long symptom durations in the community prior to presentation. Many TB patients experienced delays in diagnosis and treatment following presentation. Both pre-hospital and in-hospital delays need to be addressed in order to ‘End-TB’.
Literatur
5.
Zurück zum Zitat Farah MG, Rygh JH, Steen TW et al (2006) Patient and health care system delays in the start of tuberculosis treatment in Norway. BMC Infect Dis 24(6):33CrossRef Farah MG, Rygh JH, Steen TW et al (2006) Patient and health care system delays in the start of tuberculosis treatment in Norway. BMC Infect Dis 24(6):33CrossRef
6.
Zurück zum Zitat Golub JE, Bur S, Cronin WA et al (2005) Patient and health care system delays in pulmonary tuberculosis diagnosis in a low-incidence state. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis 9(9):992–998 Golub JE, Bur S, Cronin WA et al (2005) Patient and health care system delays in pulmonary tuberculosis diagnosis in a low-incidence state. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis 9(9):992–998
7.
Zurück zum Zitat Ibrahim WH, Alousi FH, Al-Khal A et al (2016) Diagnostic delay among adults with pulmonary tuberculosis in a high gross domestic product per capita country: reasons and magnitude of the problem. Int J Prev Med 7:116CrossRef Ibrahim WH, Alousi FH, Al-Khal A et al (2016) Diagnostic delay among adults with pulmonary tuberculosis in a high gross domestic product per capita country: reasons and magnitude of the problem. Int J Prev Med 7:116CrossRef
8.
Zurück zum Zitat Peri AM, Bernasconi DP, Galizzi N et al (2018) Determinants of patient and health care services delays for tuberculosis diagnosis in Italy: a cross-sectional observational study. BMC Infect Dis 18(1):690CrossRef Peri AM, Bernasconi DP, Galizzi N et al (2018) Determinants of patient and health care services delays for tuberculosis diagnosis in Italy: a cross-sectional observational study. BMC Infect Dis 18(1):690CrossRef
9.
Zurück zum Zitat Calder L, Gao W, Simmons G et al (2000) Tuberculosis: reasons for diagnostic delay in Auckland. N Z Med J 113(1122):483–485PubMed Calder L, Gao W, Simmons G et al (2000) Tuberculosis: reasons for diagnostic delay in Auckland. N Z Med J 113(1122):483–485PubMed
13.
Zurück zum Zitat Harpaz R, Dahl RM, Dooling KL et al (2016) Prevalence of Immunosuppression Among US Adults, 2013. JAMA 316(23):2547–2548CrossRef Harpaz R, Dahl RM, Dooling KL et al (2016) Prevalence of Immunosuppression Among US Adults, 2013. JAMA 316(23):2547–2548CrossRef
14.
Zurück zum Zitat Novosad SA, Winthrop KL (2014) Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae. Clin Infect Dis 58(11):1587–1598CrossRef Novosad SA, Winthrop KL (2014) Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae. Clin Infect Dis 58(11):1587–1598CrossRef
15.
Zurück zum Zitat Subbaraman R, Nathavitharana RR, Mayer KH et al (2019) Constructing care cascades for active tuberculosis: a strategy for program monitoring and identifying gaps in quality of care. PLoS Med 16(2):e1002754CrossRef Subbaraman R, Nathavitharana RR, Mayer KH et al (2019) Constructing care cascades for active tuberculosis: a strategy for program monitoring and identifying gaps in quality of care. PLoS Med 16(2):e1002754CrossRef
Metadaten
Titel
Symptoms to script: delays in tuberculosis treatment in the west of Ireland
verfasst von
Conor Grant
Jack McHugh
Ciara Ryan
Margaret Scarry
Anthony O’Regan
Helen Tuite
Catherine Fleming
Publikationsdatum
16.02.2021
Verlag
Springer International Publishing
Erschienen in
Irish Journal of Medical Science (1971 -) / Ausgabe 1/2022
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-021-02541-2

Weitere Artikel der Ausgabe 1/2022

Irish Journal of Medical Science (1971 -) 1/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.